Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
The American Journal of Physiology
|
May 1, 1986
Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat
E A Neuwelt, J Minna, E Frenkel, et al.
Journal of Clinical Pathology
|
July 13, 2000
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
S Wang, M H Saboorian, E Frenkel, et al.
Ophthalmic Surgery and Lasers
|
December 5, 1997
Laser trabeculoplasty: how little is enough?
R E Frenkel, D H Shin, D L Epstein, et al.
American Journal of Ophthalmology
|
November 20, 1998
Effect of topical anti-inflammatory treatment on the long-term outcome of laser trabeculoplasty. Fluorometholone-Laser Trabeculoplasty Study Group
Y Y Kim, B K Glover, D H Shin, et al.
Schizophrenia Bulletin
|
January 1, 1995
Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study
S Kugelmass, N Faber, L J Ingraham, et al.
The Journal of Laboratory and Clinical Medicine
|
November 1, 1984
Is there a "gold standard" for human serum vitamin B12 assay?
V Herbert, N Colman, D Palat, et al.
Terapevticheskii Arkhiv
|
October 20, 2001
[Correlation between severity of angina, its stability, and oxidative modification of lipids in patients with ischemic heart disease]
A L Syrkin, O A Azizov, S V Drinitsina, et al.
Klinicheskaia Meditsina
|
August 11, 2001
[Specific features of lipid atherogenic modification in patients with ischemic heart disease and diabetes mellitus]
A L Syrkin, O A Azizova, S V Drinitsina, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 1, 1981
Delivery of hexosaminidase A to the cerebrum after osmotic modification of the blood--brain barrier
E A Neuwelt, J A Barranger, R O Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
J Spicer, R Baird, A Suder, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
The American Journal of Physiology
|
May 1, 1986
Osmotic blood-brain barrier opening to IgM monoclonal antibody in the rat
E A Neuwelt, J Minna, E Frenkel, et al.
Journal of Clinical Pathology
|
July 13, 2000
Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays
S Wang, M H Saboorian, E Frenkel, et al.
Ophthalmic Surgery and Lasers
|
December 5, 1997
Laser trabeculoplasty: how little is enough?
R E Frenkel, D H Shin, D L Epstein, et al.
American Journal of Ophthalmology
|
November 20, 1998
Effect of topical anti-inflammatory treatment on the long-term outcome of laser trabeculoplasty. Fluorometholone-Laser Trabeculoplasty Study Group
Y Y Kim, B K Glover, D H Shin, et al.
Schizophrenia Bulletin
|
January 1, 1995
Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study
S Kugelmass, N Faber, L J Ingraham, et al.
The Journal of Laboratory and Clinical Medicine
|
November 1, 1984
Is there a "gold standard" for human serum vitamin B12 assay?
V Herbert, N Colman, D Palat, et al.
Terapevticheskii Arkhiv
|
October 20, 2001
[Correlation between severity of angina, its stability, and oxidative modification of lipids in patients with ischemic heart disease]
A L Syrkin, O A Azizov, S V Drinitsina, et al.
Klinicheskaia Meditsina
|
August 11, 2001
[Specific features of lipid atherogenic modification in patients with ischemic heart disease and diabetes mellitus]
A L Syrkin, O A Azizova, S V Drinitsina, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 1, 1981
Delivery of hexosaminidase A to the cerebrum after osmotic modification of the blood--brain barrier
E A Neuwelt, J A Barranger, R O Brady, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 2, 2014
Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
J Spicer, R Baird, A Suder, et al.
Page
of 5